Organizational-level, Unified and Vendor-neutral Enterprise Imaging and Informatics Drive Effective Digital Transformation
Scalable enterprise-level solutions leverage all data at an enterprise level and can engage with the entire unified longitudinal patient record SAN ANTONIO, Feb. 21, 2023 /PRNewswire/ -- Medical imaging and healthcare digitalization have seen significant advances and evolution in recent years. The COVID-19 pandemic revealed many challenges for health systems, especially regarding faculties for enterprise and external data use, exchange,...
Synbio Tech Inc. and Cosmax Group signed an exclusive cooperation agreement to jointly expand the South Korean probiotics market
KAOHSIUNG, Taiwan, Feb. 21, 2023 /PRNewswire/ -- Synbio Tech Inc. and Cosmax NBT, a major South Korean biotechnology company officially signed an exclusive cooperation agreement to launch Lactobacillus plantarum TWK10® probiotic strain in South Korea, and announced that TWK10® has been approved as an Individual Health Functional Food certification by the Ministry of Food and Drug Safety of South Korea....
Nippon Express Singapore Receives IATA CEIV Pharma Certification for Changi International Airport Facility
TOKYO, Feb. 21, 2023 /PRNewswire/ -- Nippon Express (Singapore) Pte. Ltd. (hereinafter "NX Singapore"), a group company of NIPPON EXPRESS HOLDINGS, INC., has acquired IATA CEIV Pharma (*) certification for its facility in the Free Trade Zone (FTZ) at Singapore Changi International Airport, effective Wednesday, January 17, 2023. Logo: https://kyodonewsprwire.jp/img/202302152976-O1-mlDJ2Ge9 Photo: https://kyodonewsprwire.jp/prwfile/release/M103866/202302152976/_prw_PI2fl_2k7X0YXf.jpg The pharmaceutical/medical sector, one of Singapore's priority...
Pharming announces first patient enrolled in pediatric clinical trial of leniolisib
The multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency LEIDEN, Netherlands, Feb. 21, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM)/(Nasdaq: PHAR) announces that the first patient has been enrolled in its Phase III...
Chrysalis Advisory and TriNetX Establish a Strategic Collaboration to Support Research Teams Across Australia and New Zealand
CAMBRIDGE, Mass., Feb. 21, 2023 /PRNewswire/ -- TriNetX, the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, today announced a strategic collaboration with Chrysalis Advisory, also known as Chrysalis Health Group, Australia's specialist health and medical research consulting, growth, risk, and clinical advisory group. The...
RVAC Medicines Secures HSA Approval to Initiate Phase 1B Clinical Trial in Singapore
SINGAPORE, Feb. 21, 2023 /PRNewswire/ -- RVAC Medicines Pte. Ltd. (RVAC), a messenger RNA (mRNA) technology platform company, announced today that it has secured the approval from the Health Sciences Authority (HSA) to initiate Phase 1B clinical trial in Singapore to evaluate the safety and immunogenicity of three COVID-19 mRNA vaccine candidates. The clinical trial aims to evaluate three of RVAC's...
Ascletis Presented Positive Phase I Clinical Data for Broad-Spectrum Antiviral Double Prodrug ASC10 at CROI 2023
--At the dosage of 800 mg ASC10, twice daily (BID), the exposure of the active drug, ASC10-A, is comparable to that of monupiravir's --ASC10 at 800 mg, BID is safe and well tolerated --Dosage of 800 mg ASC10, BID was selected for Phase IIa clinical trial for respiratory syncytial virus (RSV) infection in the U.S. and Phase...
iGene Laboratory Announces Launch of Whole Exome Sequencing Service
SINGAPORE, Feb. 21, 2023 /PRNewswire/ -- Singapore-based molecular diagnostics lab group iGene Laboratory announces the launch of FetalExome test service. FetalExome test is a whole exome sequencing (WES) test available for women with potentially complicated pregnancies. The test examines and analyses the gene regions that code for proteins, known as the exome, which...
Bridge Biotherapeutics Presents Phase 2a Clinical Trial Results For BBT-401, a Drug Candidate to Treat Ulcerative Colitis
BBT-401 meets safety endpoints achieved in previous clinical studies The drug candidate did not achieve an improved clinical response compared to the placebo study group 54.5% of the treatment cohort exhibited a valid treatment response to orally administered BBT-401 SEONGNAM, South Korea, Feb. 21, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company...
EDAN Pictured the Long-Term Regional Development Plans with the Minister Counselor of the Chinese Embassy in Kenya
NAIROBI, Kenya, Feb. 21, 2023 /PRNewswire/ -- Minister Counselor of the Chinese Embassy in Kenya, Yijun Zhang held a meeting on February 7, 2023 with Alex You, Global Marketing & Strategic Operations Director, and Vincent Bi, Customer Service & Healthcare Informatics Director of Edan Instruments, Inc. (300206.SZ), and Martin Chen, the Managing Director of Edan Medical (Kenya) Limited...
